Sunday, November 22, 2026

NVIDIA BioNeMo Platform Adopted by Eli Lilly and Thermo Fisher for AI Drug Discovery

Eli Lilly and Thermo Fisher Scientific have integrated NVIDIA's BioNeMo platform into drug discovery workflows, marking a shift in how pharmaceutical companies automate research. The platform provides pre-trained AI models for molecular biology tasks, positioning NVIDIA beyond hardware sales into software infrastructure. The adoption spans established pharmaceutical giants and emerging biotech firms across global markets.

This article was written by AI. Built from the source documents listed below. How we work

Source Trace Score1 source document1 with a live linkVerifiability: Basic
NVIDIA BioNeMo Platform Adopted by Eli Lilly and Thermo Fisher for AI Drug Discovery
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Eli Lilly and Thermo Fisher Scientific have adopted NVIDIA's BioNeMo platform to automate AI-driven drug discovery workflows. The platform delivers pre-trained models for protein structure prediction, small molecule generation, and genomic sequence analysis, replacing manual scientific processes with automated experimental design.

Eli Lilly is integrating BioNeMo's molecular AI capabilities into internal discovery pipelines. Thermo Fisher is embedding the platform within laboratory equipment and software systems, enabling researchers to deploy AI models alongside physical instruments. This positions NVIDIA as middleware infrastructure rather than solely a chip supplier to pharmaceutical operations.

The approach creates recurring software dependencies beyond one-time GPU purchases. As pharmaceutical companies automate research processes globally, BioNeMo becomes embedded in core operations with switching costs. The platform targets both established pharmaceutical companies digitizing legacy research and startups building AI-native discovery models.

BioNeMo provides pre-built components that reduce specialized expertise requirements for deploying AI in laboratory settings. This lowers barriers for smaller biotech firms in emerging markets while offering enterprise-grade tools for multinational pharmaceutical operations. The platform handles adaptation of general AI models to biological data formats and scientific workflows.

NVIDIA's move into domain-specific scientific tooling reflects broader industry patterns where AI infrastructure providers extend beyond general-purpose compute into specialized application layers. These vertical integrations command higher margins and stickier customer relationships across global pharmaceutical and biotech sectors. The biotech AI market spans North American pharmaceutical giants, European research institutions, and Asian biotech startups competing in drug development timelines.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· January 12, 2026
    NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 1 source document, dated 12 Jan 2026
  2. Published 23 Mar 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files

Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.